Th e loss of pigment, either partial (hypopigmentation) or complete (depigmentation), can have a major psychological impact on patients. Hypopigmentation disorders, congenital and acquired, are very numerous, and many of them are rarely seen. Th is paper provides an overview of the most common hypopigmentation disorders in children and adolescents, stressing the importance of vitiligo and autoimmune disorders in patients. Vitiligo is an acquired disease, possibly of autoimmune nature, sometimes with a clear hereditary component, which is characterized by progressive, clearly defi ned, milky white spots on the skin and/or mucous membranes. In about 50% of patients vitiligo occurs before 20 years of age. Th e clinical picture of vitiligo in children and adolescents is similar to adults, but there are some differences in the epidemiology, their associations with other endocrine and/or autoimmune diseases and treatment of vitiligo in children compared to adult patients.
Introduction
Pigmentation disorders can be congenital or acquired. Congenital disorders of pigmentation, oft en result from mutations of many genes that govern the processes of development of melanoblasts, their migratory movements towards the periphery, and their diff erentiation into mature melanocytes that produce pigment. Th e acquired pigmentation disorders are mainly due to qualitative or quantitative defects of melanocytes (e.g. vitiligo) in the skin and mucous membrane (1, 2) .
Th e loss of pigment, either partial (hypopigmentation) or complete (depigmentation), can have a major psychological impact on patients. In many religious writings, depigmentation is described as a sign of dangerous, communicable diseases (3) . In ancient times, vitiligo was equated with leprosy, in which hypopigmentation also occurs, and these patients were varying degrees of social outcasts (1, 2, 4) . Although it is now known that most hypopigmented changes in the skin are not contagious and dangerous, loss of pigment causes psychological problems for a large number of patients (5) . Many skin diseases are accompanied by hypopigmentation or depigmentation. Vitiligo, pityriasis alba and pityriasis versicolor and varietas alba are seen in everyday clinical practice, and these diseases will be discussed (6) .
Vitiligo
Vitiligo is an acquired disease, possibly autoimmune by nature, sometimes with a clear hereditary component, which is characterized by progressive, clearly circumscribed, milky white spots on the skin and/ or mucous membranes. Th e name vitiligo comes from the Latin vitium (anomaly) or vitelius (white patches on calf 's fur) (1, 2, 3).
Epidemiology
Vitiligo occurs among people of all races and climates. It is believed that 1-2% of the world's population is aff ected. It can occur in all age groups, but in half the patients it occurs before 20 years of age (1, 2, 3, 4, 7) . Some authors suggest that 25% of patients fi rst develop the symptoms before the age of eight, and 50% of patients prior to 10 years (7, 8, 9) .
Th e epidemiology of vitiligo in children is similar to adults, but there are certain characteristics of children's vitiligo. Unlike adults, where the frequency of vitiligo in both sexes is about the same, vitiligo in children is more common in girls (10) . A family history of associated endocrine and / or autoimmune disease is more common in children with vitiligo than in adult patients. Vitiligo is present in the family history of 12% to 35% of aff ected children, as opposed to about 8% of adult patients (7, 10, 11, 12) .
Th e etiology and pathogenesis of vitiligo
Th e etiology and pathogenesis of vitiligo is not fully explained. It is known that genetic factors play a role in the development of vitiligo: a positive family history in up to 30% of patients, described cases of vitiligo in twins, and the fact that vitiligo occurs with diseases that have a clear genetic basis, such as diabetes mellitus, suggests that role (3, 4, 13) . Recent research suggests two possible modes of inheritance of vitiligo, which are associated with the age at which vitiligo appeared (14) . In patients with early onset of vitiligo (before age 30), vitiligo is caused by the dominant mode of inheritance with incomplete penetration. However, in patients with late onset (aft er age 30), predisposition to vitiligo is the result of a recessive genotype and the infl uence of the external environment (15, 16 ). An earlier start of vitiligo (up to 7 years) was found in children with vitiligo and a positive family history of vitiligo (17) . Th ere is clear evidence of the association of certain MHC haplotypes with a positive family history of vitiligo, onset timing, severity of disease and ethnic origin (15, 16) . As a possible theory for the etiology of vitiligo the following are cited: the autoimmune, oxidative stress theory (theory of self-destruction of melanocytes) and the neurogenic theory (1, 2, 3, 4) . Th e autoimmune theory is supported by experimental evidence and clinical association with other autoimmune diseases: pernicious anemia, Addison's disease, type 1 diabetes mellitus (T1DM), juvenile rheumatoid arthritis, alopecia areata and especially Hashimoto's thyroiditis (1, 3, 18, 19, 20, 21) . Vitiligo is relatively common in of autoimmune polyglandular insuffi ciency syndrome (APS), especially in type I (APS-I), where 25% of patients have vitiligo (22) . Patients with vitiligo oft en have organ-specifi c serum autoantibodies, especially antithyroid (antithyroglobulin and antibodies against thyreoperoxidase) and antiparietal autoantibodies. Some research suggests that an increased incidence of autoimmune thyroiditis in patients with vitiligo is genetically determined. Th e locus on chromosome 1 -AIS1 (engl. autoimmunity susceptibility), responsible for the tendency to autoimmune responses, particularly for vitiligo, in the presence of other genes (e.g. the main histocompatibility complex localized on the short arm of chromosome 6), combined with exposure to external or internal factors, may mediate in the development of Hashimoto's thyroiditis in patients whose AIS1 is susceptible (23, 24) . It is known that genes on chromosome 17p13 contribute to the development of certain autoimmune diseases, which include generalized vitiligo, autoimmune thyroiditis, T1DM, rheumatoid arthritis, psoriasis, pernicious anemia, systemic lupus erythematosus, and Addison's disease. Recent studies describe the NALP1 protein as a gene that regulates the intactness of the immune system. Changes in the DNA sequence in the NALP1 domain, are associated with an increased risk of generalized vitiligo and/or other joint autoimmune diseases, such as autoimmune thyroiditis (25) . It is believed that autoimmune mechanisms play a key role in the pathogenesis of non-segmental vitiligo (4) .
Th e melanocytes of active vitiligo reveal an increase in oxidants and antioxidant enzyme defi cit, with resultant oxidative damage to melanocytes (3, 26, 27) . Th e emergence of segmental vitiligo can be best explained by the neurogenic theory according to which the nerve endings release the neurochemical mediators that inhibit melanogenesis or have toxic eff ects on melanocytes, destroying them. Microscopic examination and ultrastructural investigations in people with segmental vitiligo showed damage to axons and disrupted neuropeptide balance in vitiligo lesions (27, 28) . As possible provoking factors for the occurrence of vitiligo the following are cited: stress, sun burns, recurrent skin injuries. It is believed that different mechanisms may cause the same phenotype: vitiligo is a heterogeneous disease in terms of etiology (2, 4).
Clinical characteristics of vitiligo
Th e main change in vitiligo is depigmented macula, usually round or oval-shaped, milky white color, with a diameter of several millimeters to several centimeters (1, 2, 3, 4) . Th e skin surface in vitiligo is smooth. Atypical maculae (artifi cial) appear at the site of injury, lacerations, friction and burns and are the result of Köebner's phenomenon (1). Vit- In the majority of patients vitiligo lesions fi rst appear on skin exposed to the sun. In vitiligo patients polyosis commonly occurs ("white lock of hair") and halo nevus (Sutton nevus) (3). Vitiligo can be divided into the non-segmental and segmental forms of the disease (1, 2, 4, 9) . In segmental vitiligo depigmented plaques are limited to a dermatome. Th e characteristics of these two types of vitiligo are given in Table 1 . In clinical practice the generally accepted classifi cation of vitiligo is by Kovacs (3). According to this classifi cation, vitiligo is divided into focal, segmental, generalized, acrofacial and universal types, which diff er not only morphologically but also in their natural course, response to treatment and prognosis (1, 2, 3) .
Th e association of vitiligo with other endocrine and / or autoimmune diseases
Adult patients with vitiligo, especially with the generalized form of the disease, are at increased risk of developing a number of endocrine and / or autoimmune diseases, including thyroid disease, T1DM, pernicious anemia, Addison's disease, rheumatoid arthritis and alopecia areata. Vitiligo can occur before, concurrently or aft er the occurrence of one or more endocrine and / or autoimmune diseases (1, 3) . Epidemiological studies, carried out on a large number of children with vitiligo, showed no increased risk of contracting one of these endocrine and / or autoimmune diseases (10, 29, 30, 31, 32) .
Patients with vitiligo most commonly suff er from thyroid disease (30-40%), precisely Hashimoto's thyroiditis, then hyperthyroidism, hypothyroidism and GravesBasedow's disease (1, 33, 34, 35) . Unlike adults, children and adolescents with vitiligo demonstrate increased frequency of exclusively Hashimoto's thyroiditis. Considering the fact that vitiligo usually precedes autoimmune thyroiditis, a possible early diagnosis of the latter is possible. It is therefore recommended that children and adolescents with non-segmental vitiligo undergo annual screening for antibodies against thyreoperoxidase (TPO-Ab), antithyroglobulin antibodies (Tg-Ab) and thyroid-stimulating hormone (TSH) (36, 37, 38) .
Th erapy
Treatment of vitiligo should be initiated with a consultant dermatologist, aft er presenting therapeutic possibilities and their eff ectiveness to the patient. Th e choice of therapeutic options depends primarily on the age and type of vitiligo patients. In all cases it is necessary to use measures to protect against solar radiation and use photoprotective methods (1, 2, 39, 40 ).
-Phototherapy. Th ere are two basic forms of generalized vitiligo phototherapy: PUVA (Psoralen + UVA) photochemotherapy using photosensitive drug (8-metoxypsoralen) in combination with UVA radiation (320-400 nm wavelength) and UVB rays of narrow range of wavelengths of 311 nm (Narrow -band UVB). Targeted laser phototherapy is recommended for focal vitiligo (2, 41, 42). -Local corticosteroid therapy: treatment for at least 3 to 4 months (watch for side eff ects of corticosteroids!) (7). -Other forms of local therapy (melagenin, calcineurin-inhibitors / pimecrolimus, tacrolimus /, calcipotriol, pseudocatalase) (43, 44, 45) -Depigmentation (monobenzyl hydroquinone ether and 4-methoxy-phenol as a cream) with extensive and generalized vitiligo only in adults and adolescents (2).
-Surgical treatment (epidermal graft ing obtained by suction, autologous skin graft method, mini-transplantations) is the method of choice for segmental vitiligo in adults and adolescents (46). -Cosmetic camoufl age methods (47) .
Th e diff erential diagnosis of vitiligo
Th e diagnosis of vitiligo is set on the basis of history and the characteristic clinical picture, additional laboratory analysis are rarely needed, skin biopsy even rarer. In children there may be diff erential diagnostic diffi culties in relation to other diseases that are accompanied by hypopigmentation, such as pityriasis alba, pityriasis versicolor varietas alba, post-infl ammatory hypopigmentation, piebaldism, morfea, leprosy, tuberous sclerosis, naevus depigmentosus and lichen sclerosus et atrophicus (4, 6) . A special diffi culty for the recognition of vitiligo arises in fair-skinned people, where it is harder to spot hypopigmentation or depigmentation. A Wood's lamp (emitting UV rays with wavelengths of 320-400 nm, with a maximum of 365 nm), makes it possible to spot the diff erences between the complete loss of pigment in vitiligo and various other diseases accompanied by hypopigmentation. Knowing the type of inheritance, the characteristic clinical patterns and symptoms of these diseases is necessary to set an accurate diagnosis of vitiligo (4, 6, 11) .
Pityriasis alba
Pityriasis alba (PA) is a common, benign, localized form of hypopigmentation, which is more common in children than in adults. In children under 12 years of age, prevalence is between 1.9% and 5.25% (2, 48) .
Th e etiology and pathogenesis of PA is not clarifi ed. Th ere is a perception that the disease is more common in dark-skinned people. PA is considered a minor form of atopic dermatitis. Recent studies have indicated the frequent occurrence of PA in individuals who sunbathe without using photoprotection, and the onset of PA as a result of frequent sunbathing. In these patients the low levels of serum copper was detected, and it is known that copper plays an important role in the synthesis of tyrosinase, which may explain the hypopigmentation (6, 48) .
Th e clinical pattern shows unclearly bordered hypopigmented maculae and pityriasis-like desquamation on their surface. Th e disease begins with an erythematous plaque with elevated edges and desquamation occurs aft er several weeks. Hypopigmentation can last from 6 months to 7 years. Th e course is prolonged in patients with atopic dermatitis. PA is an asymptomatic disease, although there may be mild itching. Th e changes are mainly localized on the head, neck and upper limbs. Th e most common localizations are the head, the forehead and cheekbones, and it rarely occurs in periorbital and perioral regions, unlike vitiligo. Th ere is a generalized form of atypical PA, which is more oft en seen in adults, and the changes are localized to the thorax (1, 2, 6, 48) .
Th e therapy involves emollients and corticosteroid creams of low and moderate potency, which have limited eff ectiveness. Th e use photoprotective creams is recommended. Aft er a few months or years the condition spontaneously withdraws. In the extensive form in adolescents and adults PUVA therapy is applied (48) .
Pityriasis versicolor alba varietas
Th e cause of the disease is Pityrosporum ovale (synonyms: Pityrosporum orbiculare, Malassezia furfur, Malassezia ovalis), part of the normal fl ora of the skin, which under certain circumstances is transformed from saprophytic yeasts into the mycelal phase and leads to skin diseases. Th e disease is not contagious and occurs in predisposed peo-ple, mostly in areas with a humid and warm climate (6, 49) .
Th e clinical picture is presented with café-au-lait or yellowish-brown (versicolor) maculae which are circular, oval or irregular in shape, with unclear edges, up to 1 cm in diameter, with pityriasis-like desquamation at the surface (apparent aft er mild curretage of the macula) and with a tendency to confl uence in plaques. Th e maculae have characteristic distribution sites, with localization on the chest, back and upper half of the upper arm, and in children they occur on the head and neck. In immunodefi cient conditions, the skin changes have atypical distribution (inverse) and the face, creases and some parts of the limbs are aff ected. Th e maculae become hypopigmented aft er sunbathing (Pityriasis versicolor alba varietas) but hypopigmentation is reversible. An asymptomatic infection is the most common, itching is rarely present. If left untreated, the course becomes chronic and could last for years (49) .
Diagnosis is made based on the clinical features and the use of a Wood's lamp, when the yellowish-orange fl uorescence of the affected skin is noticed. Native mycological examination with KOH reveals the characteristic appearance of hyphae and spores ("spaghetti and meatballs") (6, 48, 49) .
Local therapy is the method of choice, and imidazole compounds are advised (1% Econazole, Ketoconazole 2%) and ciclopiroxolamine in the form of a solution, spray or cream 1-2 times a day for 2-4 weeks. Selenium sulfi de 2.5% shampoo and zinc pyrithione shampoo used once a day (foam should be left on the skin 10 minutes), for two weeks. Residual hypopigmentation lasts a few months aft er healing, which patients should be warned about. Th e disease may recur, since Pityrosporum ovale belongs to the normal saprophytic fl ora of the skin. Systemic therapy is not recommended because Pityrosporum ovale is a normal inhabitant of the skin and cannot be completely removed. For prevention of the disease, a soap is recommended containing Zn and Se sulfi de for washing, with mild friction with keratolytics during the summer months as well as the use of a sulfi de shampoo with Se and Zn pyrithione, once a week (6, 48, 49) .
Piebaldism
Piebaldism is a rare (incidence is 2.5/100000) autosomal dominant disorder caused by the irregular development of melanocytes, which is manifested by the focal absence of melanocytes in the aff ected skin and hair follicles. Th e clinical picture is characterized by polyosis and multiple, symmetrical, leukodermic maculae, typically distributed on the sides of the trunk, the anterior abdominal wall and above and below the elbows and knees. Polyosis on the forehead is present in 80-90% of patients. Unlike vitiligo, piebaldism does not appear on the hands, feet and periorifi cial areas. Hyperpigmented maculae within amelanotic depigmented areas are typical (1, 2, 4) .
In patients with piebaldism mutations of C-kit proto-oncogene are found, which encodes the transmembrane receptor and tyrosine kinase activity, causing the omission of migration and diff erentiation of melanoblasts from the neural tube during embryonic development, in the aff ected skin areas. Phenotypic characteristics are fully formed at birth and permanent, and usually do not spread aft erwards (1, 2). Th erapy is symptomatic and includes photoprotection and allows the use of cosmetic camoufl age (1, 2).
Tuberous sclerosis
Tuberous sclerosis is an autosomal dominant determined, multisystemic neurocutaneous syndrome, characterized by the formation of multiple hamartomas usually localized in the skin, brain, heart, kidney, liver and lungs. In 2/3 of the patients the disease is the result of sporadic mutations. Th e char-acteristic triad consists of deafness, mental retardation and cutaneous angiofi bromas, and is seen in only 29% of patients. Early diagnosis is important. At birth or during the fi rst months of life in 97.2% of patients hypopigmented maculae are observed (3 or more), beige-whitish or yellow-whitish in color. Th ey represent a major diagnostic sign. Ash-leaf spots or spear-like and polygonal maculae, sized 0.5 to 2 cm, localized mainly on the trunk or upper legs are characteristic. Less commonly confetti macula or macula of dermatome schedule are seen. Size can vary from 4 mm to 12 cm. Later, chagrin plate, facial angiofi bromas, periungual fi bromas and plaque on the forehead could emerge. Systemic manifestations of tuberous sclerosis fall within the scope of pediatrics (1, 2, 4, 50).
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